Cite
HARVARD Citation
McBride, A. et al. (2017). Cost-efficiency analyses for the US of biosimilar filgrastim-sndz, reference filgrastim, pegfilgrastim, and pegfilgrastim with on-body injector in the prophylaxis of chemotherapy-induced (febrile) neutropenia. Journal of medical economics. pp. 1083-1093. [Online].